These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884 [TBL] [Abstract][Full Text] [Related]
5. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K Front Immunol; 2021; 12():611366. PubMed ID: 33708205 [TBL] [Abstract][Full Text] [Related]
6. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Read JA; Rouce RH; Mo F; Mamonkin M; King KY Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718 [TBL] [Abstract][Full Text] [Related]
7. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Zhang H; Lv X; Kong Q; Tan Y Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 35049413 [TBL] [Abstract][Full Text] [Related]
8. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model]. Shan JQ; Nan SF; Li F; Shen CY; Zhang Y Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632 [No Abstract] [Full Text] [Related]
9. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474 [TBL] [Abstract][Full Text] [Related]
10. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Brudno JN; Kochenderfer JN Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964 [TBL] [Abstract][Full Text] [Related]
12. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia. Li J; Wu Z; Zhao N Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935 [TBL] [Abstract][Full Text] [Related]
13. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. Mansouri V; Yazdanpanah N; Rezaei N Int Rev Immunol; 2022; 41(6):649-668. PubMed ID: 34607523 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. Tedesco VE; Mohan C J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146 [TBL] [Abstract][Full Text] [Related]
16. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212 [TBL] [Abstract][Full Text] [Related]
18. The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells. Futami M; Suzuki K; Kato S; Ohmae S; Tahara Y; Nojima M; Imai Y; Mimura T; Watanabe Y; Tojo A PLoS One; 2020; 15(4):e0231896. PubMed ID: 32320454 [TBL] [Abstract][Full Text] [Related]
19. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Wei Z; Xu J; Zhao C; Zhang M; Xu N; Kang L; Lou X; Yu L; Feng W Front Immunol; 2023; 14():1273507. PubMed ID: 37854590 [TBL] [Abstract][Full Text] [Related]
20. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]